IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA) announced its upcoming participation in two key events: the Jefferies London Healthcare Conference on November 19th, 2024, featuring a fireside chat with CEO Yujiro S. Hata, and an Investor R&D Day scheduled for December 16th, 2024. The R&D Day will showcase IDEAYA's potential first-in-class preclinical and clinical pipeline, featuring presentations from management, Key Opinion Leaders, and pharmaceutical partners. Both events will be accessible via webcast through IDEAYA's investor relations website, with recordings available for 30 days after the live events.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, IDYA declined 3.13%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Jefferies London Healthcare Conference
Tuesday, November 19th, 2024 at 10:00 AM GMT | 5:00 AM ET
- Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology
IDEAYA Biosciences Investor R&D Day
Monday, December 16th, 2024 at 8:00 AM ET
- The IDEAYA Investor R&D Day will highlight IDEAYA's potential first-in-class preclinical and clinical pipeline with management, leading Key Opinion Leader(s) (KOLs), and Pharma partner(s)
- Pre-registration will be available through IDEAYA's investor relations events page at https://ir.ideayabio.com/events, or https://lifescievents.com/event/ideaya-4/
A live audio webcast of the conference event, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-participation-in-jefferies-london-healthcare-conference-and-plans-for-investor-rd-day-302302062.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) hosting its Investor R&D Day in 2024?
When is IDEAYA Biosciences (IDYA) presenting at the Jefferies London Healthcare Conference?
Where can investors access the webcast for IDEAYA Biosciences (IDYA) events?
